western medicine

西医
  • 文章类型: Journal Article
    背景:良性前列腺增生(BPH)在老年男性人群中普遍存在,并且经常表现出令人痛苦的下尿路症状。有新的证据表明,在BPH治疗中,与单独的WM相比,商业口服多草药中药(TCM)制剂与西药(WM)组合可以提供增强的治疗效果。然而,确定BPH的最佳配方仍存在争议。我们旨在采用网络荟萃分析来比较和评估中国BPH治疗指南中概述的常用和推荐的多草药中药配方之间的差异。提供临床用药建议和指导。方法:我们广泛搜索BPH患者的RCT,这些患者有口服复方中药和WM治疗,涵盖截至2023年10月31日的英文和中文数据库。使用Cochrane偏倚风险工具第2版(ROB2)评估纳入研究的质量。进行了贝叶斯网络荟萃分析,以评估各种配方的有效性,其次是敏感性和亚组分析。结果:我们的荟萃分析包括107项RCTs,涉及16种口服复方中药配方的11,037例患者。所选研究的质量被评估为“一些问题”。与单独的WM相比,与WM组合的大多数制剂表现出优异的治疗功效。临床有效率,金桂参芪丸(JGSQ)+WM的概率最高(87.38%)。关于国际前列腺症状评分(IPSS)和最大尿流率,桂枝茯苓胶囊(GZFL)+WM最有效(91.10%和98.55%)。关于生活质量评分和后尿残留,Pulean片(PLA)+WM排名第一(86.71%和91.81%)。在控制前列腺体积方面,环葛胶囊(HE)+WM疗效最高(95.65%)。此外,在干预措施中,灵泽(LZ)+WM胶囊不良反应发生率最低(2.32%)。结论:与单独使用WM相比,口服中药复方制剂与WM联合治疗BPH可提供更大的治疗效果。JGSQ,GZFL,PLA,他成为有希望的治疗选择。然而,进一步严格的实证研究对于证实这些发现至关重要。系统审查注册:https://www。crd.约克。AC.uk/prospro/display_record.php?RecordID=459651,CRD42023459651。
    Background: Benign prostatic hyperplasia (BPH) is prevalent among the aging male population and often presents with distressing lower urinary tract symptoms. There is emerging evidence that commercial oral poly-herbal traditional Chinese medicine (TCM) formulation combined with Western medicine (WM) may offer enhanced therapeutic effects compared to WM alone in BPH treatment. Nevertheless, determining the optimal formulations for BPH remains controversial. We aimed to employ a network meta-analysis to compare and assess differences among commonly used and recommended poly-herbal TCM formulations outlined in the Chinese guidelines for BPH treatment, providing clinical medication recommendations and guidance. Methods: We extensively searched for RCTs of BPH patients that had oral poly-herbal TCM formulations and WM treatment, covering both English and Chinese databases up to 31 October 2023. The quality of the included studies was evaluated using the Cochrane risk-of-bias tool Version 2 (ROB2). A Bayesian network meta-analysis was performed to assess the effectiveness of various formulations, followed by sensitivity and subgroup analyses. Results: Our meta-analysis included 107 RCTs involving 11,037 patients across 16 oral poly-herbal TCM formulations. The quality of the selected studies was assessed as \"Some concerns\". Most formulations combined with WM demonstrated superior therapeutic efficacy compared to WM alone. For clinical effective rate, Jingui Shenqi pill (JGSQ) + WM had the highest-ranking probability (87.38%). Concerning International Prostate Symptom Score (IPSS) and maximum flow rate of urine, Guizhi Fuling capsule (GZFL) + WM was most effective (91.10% and 98.55%). Regarding the quality of life score and postvoid residual urine, Pulean tablet (PLA) + WM ranked first (86.71% and 91.81%). In controlling prostate volume, Huange capsule (HE) + WM demonstrated the highest efficacy (95.65%). Additionally, among the interventions, Lingze (LZ) + WM capsule exhibited the lowest incidence of adverse drug reactions (2.32%). Conclusion: Combining oral poly-herbal TCM formulations with WM may provide greater therapeutic benefits in BPH treatment compared to WM alone. JGSQ, GZFL, PLA, and HE emerged as promising treatment options. However, further rigorous empirical studies are essential to substantiate these findings. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=459651, CRD 42023459651.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    脑梗死(CI)是世界范围内常见的脑血管病,CI后遗症带来的负担明显增加。然而,目前的治疗指南缺乏CI后遗症药物治疗的标准化建议。这项回顾性研究收集并分析了2022年在智云健康互联网医院住院的198万张有关CI后遗症的处方。患者平均年龄为66.2±11.4岁,男性占52.40%。79.73%有一种或多种合并症。为了治疗,1-的处方,2-和≥3-药物占64.55%,分别为23.77%和11.68%。中成药(CPM)处方,西医(WM)处方,CPM和WM合并(CPM+WM)处方占53.81%,27.33%,和18.86%。在CPM处方中,最常用的处方药是丹参(34.81%),银杏(24.96%),三七(20.67%),天麻(7.15%)和川麻(4.90%)。对于WM处方,最常用的处方药是抗高血压药(32.82%),抗血栓(16.06%),血管扩张剂(15.70%),抗痴呆(10.88%),和降脂药(9.58%)。在CPM+WM处方中,72.61%的CPM/WM=1,21.20%的CPM/WM<1,6.19%的CPM/WM>1。这项研究利用了从中国互联网医院提取的真实数据,为患有CI后遗症的患者提供了在线处方模式的宝贵证据。
    Cerebral infarction (CI) is a common cerebrovascular disease worldwide, and the burden caused by the sequelae of CI has increased significantly. However, current treatment guidelines lack standardized recommendations for pharmacotherapy of sequelae of CI. This retrospective study collected and analyzed 1.98 million prescriptions concerning sequelae of CI from patients admitted to Zhiyun Health Internet Hospital in 2022. The mean age of patients was 66.2 ± 11.4 years, and 52.40% were male. 79.73% had one or more comorbidities. For treatment, the prescriptions of 1-, 2- and ≥ 3-drug accounted for 64.55%, 23.77% and 11.68% respectively. Chinese patent medicine (CPM) prescriptions, western medicine (WM) prescriptions, and CPM and WM combined (CPM + WM) prescriptions accounted for 53.81%, 27.33%, and 18.86% respectively. In CPM prescriptions, the most frequently prescribed medications were Salvia miltiorrhiza (34.81%), Ginkgo biloba (24.96%), Panax notoginseng (20.67%), Gastrodia (7.15%) and Ligusticum Wallichii (4.90%). For WM prescriptions, the most commonly prescribed agents were anti-hypertensive (32.82%), anti-thrombotic (16.06%), vasodilator (15.70%), anti-dementia (10.88%), and lipid-lowering (9.58%) drugs. Among CPM + WM prescriptions, 72.61% had CPM/WM = 1, 21.20% had CPM/WM < 1, and 6.19% had CPM/WM > 1. This research utilized real-world data extracted from internet hospitals in China to present valuable evidence of online prescription patterns among patients experiencing sequelae of CI.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    太空环境中的微重力可能会对人体产生各种负面影响,其中之一是骨质流失。鉴于人类空间活动的频率越来越高,目前迫切需要为微重力环境寻找有效的抗骨质疏松药物。在太空中进行的传统微重力实验受到诸如耗时的程序等限制,高成本,和小样本量。近年来,由于生物信息学和计算机技术的进步,计算机药物发现方法已成为一种有前途的策略。在这项研究中,我们首先收集了184915篇与微重力和骨质流失相关的文献.我们采用了依赖路径提取和聚类技术的组合来从文本中提取数据。之后,我们进行了数据清理和标准化,以整合来自多个来源的数据,包括全球生物医学关系网络(GNBR),精选的药物-药物相互作用数据库(DDInter),相互作用化学品搜索工具(STITCH),DrugBank,和中药综合数据库(TCMID)。通过这一整合过程,我们构建了由134,796个生物实体和3,395,273个三胞胎组成的微重力生物学知识图谱(MBKG)。随后,利用TransE模型进行知识图嵌入。通过计算模型空间中实体之间的距离,该模型成功预测了治疗骨质疏松症和微重力诱导的骨丢失的潜在药物。结果表明,在排名前10位的西药中,7已被批准用于治疗骨质疏松症。此外,在排名前十的中药中,5有科学文献支持其治疗骨丢失的有效性。在微重力诱导的骨丢失的前20种预测药物中,已经在微重力或模拟微重力环境中研究了15个,其余5种也适用于治疗骨质疏松症。这项研究突出了MBKG在太空药物发现领域的潜在应用。
    Microgravity in the space environment can potentially have various negative effects on the human body, one of which is bone loss. Given the increasing frequency of human space activities, there is an urgent need to identify effective anti-osteoporosis drugs for the microgravity environment. Traditional microgravity experiments conducted in space suffer from limitations such as time-consuming procedures, high costs, and small sample sizes. In recent years, the in-silico drug discovery method has emerged as a promising strategy due to the advancements in bioinformatics and computer technology. In this study, we first collected a total of 184,915 literature articles related to microgravity and bone loss. We employed a combination of dependency path extraction and clustering techniques to extract data from the text. Afterwards, we conducted data cleaning and standardization to integrate data from several sources, including The Global Network of Biomedical Relationships (GNBR), Curated Drug-Drug Interactions Database (DDInter), Search Tool for Interacting Chemicals (STITCH), DrugBank, and Traditional Chinese Medicines Integrated Database (TCMID). Through this integration process, we constructed the Microgravity Biology Knowledge Graph (MBKG) consisting of 134,796 biological entities and 3,395,273 triplets. Subsequently, the TransE model was utilized to perform knowledge graph embedding. By calculating the distances between entities in the model space, the model successfully predicted potential drugs for treating osteoporosis and microgravity-induced bone loss. The results indicate that out of the top 10 ranked western medicines, 7 have been approved for the treatment of osteoporosis. Additionally, among the top 10 ranked traditional Chinese medicines, 5 have scientific literature supporting their effectiveness in treating bone loss. Among the top 20 predicted medicines for microgravity-induced bone loss, 15 have been studied in microgravity or simulated microgravity environments, while the remaining 5 are also applicable for treating osteoporosis. This research highlights the potential application of MBKG in the field of space drug discovery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    医学的进步将一种相对虚构的死亡引入了我们的生活:脑死亡。由于知道心脏在跳动,它与我们对经典死亡的看法交织在一起,皮肤的颜色是粉红色,和身体的温度是温暖的。因此,就脑死亡的亲属而言,接受脑死亡可能会变得复杂。采访显示,不愿捐献尸体器官与死亡的文化观念密切相关。此外,民间传说干扰了利他主义的尸体捐赠,尤其是民间信仰,仪式,社会规范,口头传统。
    Advancements in medicine introduced a relatively invented death into our lives: Brain Death. It intermingles with our perceptions of classical death due to knowing the heart is beating, the color of the skin is pink, and the body\'s temperature is warm. Hence, accepting brain death as death might get complicated in terms of relatives of the brain-dead person. The interviews revealed that the reluctance to cadaveric organ donations is highly connected to the cultural perception of death. Furthermore, folklore interferes with altruistic cadaveric donations, particularly folk beliefs, rituals, social norms, and oral traditions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Qi在西方继续被怀疑地翻译为圣经中的生命力概念。气的真正含义可能更接近西方科学定义的能量是宇宙中万物的物质基础。为了说明这一点,中国古代思想家的著作与西方对能量的定义有相似之处,包括西方科学思想的热力学定律和中国科学思想的阴阳理论。重点是物质现实理论的相似性,同时承认文化思维方式的差异如何创造出相同想法的不同描述风格。建立更准确的气翻译的目的,通过删除西方的预测,是为了改善患者与医生的沟通,并消除接受针灸和中医作为西方主流医疗干预的障碍。
    Qi continues to be questionably translated in the West as the biblical idea of lifeforce. The true meaning of qi may be closer to the Western scientific definition of energy as the material basis of everything in the Universe. To illustrate this, parallels are drawn between the writings of ancient Chinese thinkers and Western definitions of energy, including the laws of thermodynamics underlying Western scientific thought and yin-yang theory underlying Chinese scientific thought. The focus is on the similarities in theories of material reality while acknowledging how differences in cultural mindset create distinct styles of description of the same ideas. The purpose in establishing a more accurate translation of qi, by removing Western projections, is to improve patient-practitioner communication and to remove obstacles to the acceptance of acupuncture and Traditional Chinese Medicine as a mainstream medical intervention in the West.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    中药(TCM)已被广泛用于代谢疾病几个世纪,包括非酒精性脂肪性肝病(NAFLD)。目前,NAFLD已成为世界范围内最常见的慢性肝病,并可发展为非酒精性脂肪性肝炎(NASH),肝硬化,甚至肝细胞癌。然而,西医仍缺乏有效的治疗策略。NAFLD的发展是由多种机制驱动的,包括遗传因素,胰岛素抵抗,脂毒性,线粒体功能障碍,内质网应激,炎症,肠道菌群失调,和脂肪组织功能障碍。目前,某些药物,包括胰岛素增敏剂,他汀类药物,维生素E,熊去氧胆酸和甜菜碱,被证明对NAFLD的临床治疗有益。由于其复杂的发病机制,整合各种机制的个性化医疗可能为NAFLD患者提供更好的益处.中医整体观和辨证治疗NAFLD具有优势,类似于个性化医疗的原理。在中医,根据临床经验,NAFLD主要分为五种类型。它位于肝脏,与脾和肾功能密切相关。然而,由于中药的多组分特点,其在NAFLD治疗中的应用受到很大限制。在这次审查中,本文就NAFLD的发病机制和治疗进展作一综述,从西医和中医的角度来看。强调中西医结合具有互补优势,在NAFLD的预防和治疗中应该得到更多的重视。
    Traditional Chinese medicine (TCM) has been widely used for several centuries for metabolic diseases, including non-alcoholic fatty liver disease (NAFLD). At present, NAFLD has become the most prevalent form of chronic liver disease worldwide and can progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. However, there is still a lack of effective treatment strategies in Western medicine. The development of NAFLD is driven by multiple mechanisms, including genetic factors, insulin resistance, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, inflammation, gut microbiota dysbiosis, and adipose tissue dysfunction. Currently, certain drugs, including insulin sensitizers, statins, vitamin E, ursodeoxycholic acid and betaine, are proven to be beneficial for the clinical treatment of NAFLD. Due to its complex pathogenesis, personalized medicine that integrates various mechanisms may provide better benefits to patients with NAFLD. The holistic view and syndrome differentiation of TCM have advantages in treating NAFLD, which are similar to the principles of personalized medicine. In TCM, NAFLD is primarily classified into five types based on clinical experience. It is located in the liver and is closely related to spleen and kidney functions. However, due to the multi-component characteristics of traditional Chinese medicine, its application in the treatment of NAFLD has been considerably limited. In this review, we summarize the advances in the pathogenesis and treatment of NAFLD, drawn from both the Western medicine and TCM perspectives. We highlight that Chinese and Western medicine have complementary advantages and should receive increased attention in the prevention and treatment of NAFLD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    非小细胞肺癌(NSCLC)绝大多数代表肺癌的主要组织学亚型,肺腺癌是最常见的形式。传统的西方医学治疗包括一系列的模式,包括外科手术,细胞毒性化疗,放射治疗,靶向药物治疗,和免疫疗法。相比之下,中医(TCM)方法包括中医治疗,针灸治疗,和推拿治疗。虽然常规西医治疗肺癌取得了显著进展,重要的是要承认单一治疗方法固有的局限性。因此,寻求更全面和综合的治疗范式变得势在必行。在中医领域中,针对肺腺癌治疗的评估标准的不足代表了需要解决的突出挑战。尽管如此,在肺腺癌治疗方式不断演变的背景下,中西医结合治疗这种疾病的方法表现出了有希望的轨迹。它不仅有助于减轻毒性和提高疗效,还有助于减少一系列术后并发症。从而提高患者的生存质量和延长预期寿命。本文对中西医结合治疗肺腺癌的研究进展进行了全面综述。它阐明了个人和联合治疗策略的优缺点,超越电流限制,强调了中西医结合医学范式的优点,并提供了一个更全面的,集成,和有效的治疗蓝图。
    Non-small cell lung cancer (NSCLC) overwhelmingly represents the predominant histological subtype of lung cancer, with lung adenocarcinoma emerging as the most prevalent form. Conventional Western medical treatments encompass a spectrum of modalities, including surgical interventions, cytotoxic chemotherapy, radiotherapy, targeted pharmacotherapy, and immunotherapy. In contrast, Traditional Chinese Medicine (TCM) methodologies encompass traditional Chinese medicine treatments, acupuncture therapies, and tuina treatments. While conventional Western medicine has made remarkable strides in the treatment of lung cancer, it is important to acknowledge the limitations inherent in singular treatment approaches. Consequently, the quest for a more comprehensive and integrative therapeutic paradigm becomes imperative. A deficiency of evaluation criteria specific to lung adenocarcinoma treatment in the realm of TCM represents an outstanding challenge in need of resolution. Nonetheless, in the backdrop of the continuous evolution of lung adenocarcinoma treatment modalities, the amalgamation of Chinese and Western medical approaches for treating this condition has exhibited a promising trajectory. It not only contributes to mitigating toxicity and augmenting efficacy but also serves to reduce a spectrum of postoperative complications, thereby enhancing the quality of patients\' survival and extending life expectancy. This article furnishes a comprehensive survey of the research advancements in the integration of Chinese and Western medical approaches for treating lung adenocarcinoma. It elucidates the merits and demerits of individual and combined therapeutic strategies, surmounts current limitations, underscores the virtues of amalgamating Chinese and Western medical paradigms, and offers a more holistic, integrated, and efficacious treatment blueprint.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    背景:中医(TCM)和西医的临床试验表明,心肌梗死(MI)的结局报告存在异质性。开发核心结果集(COS)可能会提高未来临床试验结果报告的一致性。
    方法:基于对MI的随机对照试验(RCTs)和对MI患者的半结构化访谈的系统评价,制定了一系列结果。两轮德尔菲临床医生调查,研究人员,期刊编辑,和方法学家进行了。在线问卷发送给护士。在一次在线共识会议之后,开发了MIRCT的COS。
    结果:在从临床试验中提取数据并进行讨论之后,216个结果被纳入Delphi调查的第1轮。74名参与者完成了Delphi调查的第一轮。65名参与者完成了德尔福调查的第二轮。22名护士完成了在线调查问卷。十五名与会者参加了网上共识会议,其中14人投票并决定了最终的COS。对于所有类型的MI,建议测量和报告左心室射血分数和生活质量.对于急性MI,共识会议的参与者推荐了以下核心结果:心脑血管疾病死亡,心源性休克,心力衰竭,肌钙蛋白I,肌钙蛋白T,肌酸激酶同工酶,基利普班,靶血管血运重建,紧急CABG。对于以前的MI,复发性MI,复发性心绞痛,并建议心力衰竭再入院.
    结论:RCT中MI的COS为寻求改善MI患者预后的临床试验提供了建议。
    BACKGROUND: Clinical trials of traditional Chinese medicine (TCM) and Western medicine showed there was heterogeneity of outcome reporting in myocardial infarction (MI). Developing a core outcome set (COS) might improve the consistency of outcome reporting in future clinical trials.
    METHODS: A list of outcomes was developed based on a systematic review of randomized controlled trials (RCTs) of MI and semistructured interviews with MI patients. Two rounds of Delphi survey for clinicians, researchers, journal editors, and methodologists were conducted. An online questionnaire sent to nurses. After an online consensus meeting, a COS for MI RCTs was developed.
    RESULTS: After extracted data from clinical trials and discussed, 216 outcomes were included in round 1 of the Delphi survey. Seventy-four participants completed round 1 of the Delphi survey. Sixty-five participants completed round 2 of the Delphi survey. Twenty-two nurses completed the online questionnaire. Fifteen participants attended the online consensus meeting, and 14 of them voted and determined the final COS. For all types of MI, it was recommended that left ventricular ejection fraction and quality of life be measured and reported. For acute MI, the participants in the consensus meeting recommended the following core outcomes: death from cardio-cerebrovascular disease, cardiogenic shock, heart failure, troponin I, troponin T, creatine kinase isoenzyme, Killip class, target vessel revascularization, and emergency CABG. For previous MI, recurrent MI, recurrent angina pectoris, and heart failure readmission were recommended.
    CONCLUSIONS: The COS for MI in RCTs provides recommendations for clinical trials that seek to improve outcomes for patients with MI.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    传统医学和生物医学医学之间的合作可以为患有精神疾病的人带来整体护理和改善健康状况。本研究旨在探讨中西医结合医生对布兰太尔精神病患者护理的潜在合作的观点和经验,马拉维。
    采用了现象学定性研究设计。使用一对一深度访谈(IDI)和焦点小组讨论(FGD)收集数据。参与者是布兰太尔的传统治疗师和西医从业者,马拉维。我们对传统治疗师进行了10次深度访谈,4次焦点小组讨论(2次针对传统治疗师,2次针对西医从业者)和6次与两组领导人的关键线人访谈。基于数据饱和度确定样品。采用专题分析法对数据进行分析。我们使用了演绎和归纳编码的组合。
    从数据中确定了五个广泛的主题:合作经验,对合作的看法,合作模式,合作的障碍,以及可以促进合作的因素。参与者没有传统治疗师和西方医护人员在精神疾病管理方面进行正式合作的经验.然而,据报道,在安全孕产等其他卫生领域成功合作的一些经验,结核病和艾滋病毒/艾滋病。许多参与者对合作表现出积极的态度,并对此表示支持。合作的障碍包括消极态度和缺乏资源。可以促进合作的因素是对话,训练和尊重。推荐和培训是首选的合作形式。
    通过适当的结构和尊重的对话,在布兰太尔,传统和西医之间的合作是可能的,马拉维。
    UNASSIGNED: Collaboration between traditional and biomedical medicine can lead to holistic care and improved health outcomes for people with mental illnesses. The current study aimed to explore the views and experiences of traditional and western medicine practitioners on potential collaboration in the care of people living with mental illness in Blantyre, Malawi.
    UNASSIGNED: A phenomenological qualitative research design was used. Data were collected using both one-on-one in-depth interviews (IDIs) and focus group discussions (FGDs). Participants were traditional healers and western medicine practitioners in Blantyre, Malawi. We conducted 10 in-depth interviews with traditional healers, 4 focus group discussions (2 for traditional healers and 2 for western medicine practitioners) and 6 key informant interviews with leaders of the two groups. The sample was determined based on data saturation. Thematic analysis was used to analyse the data. We used a combination of deductive and inductive coding.
    UNASSIGNED: Five broad themes were identified from the data: experiences with collaboration, views on collaboration, models of collaboration, barriers to collaboration, and factors that can facilitate collaboration. participants had no experience of formal collaboration between traditional healers and western healthcare workers in the management of mental illness. However, some reported experience of successful collaborations in other health areas such as safe motherhood, tuberculosis and HIV/AIDS. Many participants showed a positive attitude toward collaboration and were in support of it. Barriers to collaboration included negative attitudes and a lack of resources. Factors that can facilitate collaboration were dialogue, training and respect. Referral and training were the preferred forms of collaboration.
    UNASSIGNED: With proper structures and respectful dialogue, a collaboration between traditional and western medicine practitioners is possible in Blantyre, Malawi.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Comparative Study
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号